CRL
Charles River Laboratories International, Inc. NYSE Listed Jun 23, 2000$185.00
After hrs
$185.37
+0.20%
Mkt Cap $8.9B
52w Low $144.26
48.1% of range
52w High $228.88
50d MA $174.36
200d MA $177.89
P/E (TTM)
-62.7x
EV/EBITDA
12.5x
P/B
2.9x
Debt/Equity
1.0x
ROE
-4.6%
P/FCF
17.7x
RSI (14)
54.40
ATR (14)
$7.24
Beta
1.62
50d MA
$174.36
200d MA
$177.89
Avg Volume
894.7K
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
251 Ballardvale Street · Wilmington, MA 01887 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 181.73 | +4.2% | -0.0% | -2.2% | -5.2% | +0.1% | -3.5% | — |
| Feb 18, 2026 | AMC | 2.33 | 2.39 | +2.6% | 158.00 | -2.5% | +3.9% | +2.8% | -3.2% | +1.6% | +0.9% | — |
| Nov 5, 2025 | AMC | 2.32 | 2.43 | +4.7% | 167.70 | +0.0% | +1.9% | -1.7% | +0.5% | +2.7% | -1.2% | — |
| Aug 6, 2025 | AMC | 2.50 | 3.12 | +24.8% | 150.33 | +2.0% | -0.4% | -0.7% | +0.1% | +2.6% | +1.5% | — |
| May 7, 2025 | AMC | 2.06 | 2.34 | +13.6% | 136.97 | +2.7% | +3.2% | -1.8% | +3.1% | +0.7% | -3.5% | — |
| Feb 19, 2025 | AMC | 2.50 | 2.66 | +6.4% | 165.00 | +0.0% | -1.7% | +0.5% | +4.6% | -2.0% | +0.5% | — |
| Nov 6, 2024 | AMC | 2.42 | 2.59 | +7.0% | 214.20 | +0.7% | -1.8% | +2.4% | +2.5% | -2.2% | -4.4% | — |
| Aug 7, 2024 | AMC | 2.39 | 2.80 | +17.2% | 199.96 | -4.2% | +1.0% | -0.5% | -3.3% | +4.7% | -2.4% | — |
| May 9, 2024 | AMC | 2.06 | 2.27 | +10.2% | 230.09 | +0.1% | -0.9% | +0.1% | +1.9% | -0.1% | -3.4% | — |
| Feb 14, 2024 | AMC | 2.39 | 2.46 | +2.9% | 245.12 | -1.2% | +0.1% | -0.2% | -2.5% | +0.9% | +2.4% | — |
| Nov 8, 2023 | AMC | 2.35 | 2.72 | +15.7% | 175.97 | +0.7% | -3.7% | +1.5% | -1.1% | +4.9% | +5.2% | — |
| Aug 9, 2023 | AMC | 2.63 | 2.69 | +2.3% | 215.80 | +0.1% | +0.8% | -1.4% | +1.1% | -3.1% | -3.9% | — |
| May 11, 2023 | AMC | 2.59 | 2.78 | +7.3% | 195.75 | +0.6% | -2.3% | +0.6% | -2.2% | +4.6% | +1.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 17 | Morgan Stanley | Upgrade | Equal-Weight → Overweight | $220 | $184.79 | $188.81 | +2.2% | -1.3% | — | — | — | — |
| May 29 | CLSA | Upgrade | Hold → Outperform | $219 | $181.34 | $181.34 | +0.0% | -0.3% | +0.8% | -4.0% | +2.9% | +3.3% |
| Apr 14 | Barclays | Maintains | Overweight → Overweight | — | $178.34 | $181.90 | +2.0% | +0.5% | +0.7% | -2.0% | +3.9% | +0.9% |
| Apr 13 | JP Morgan | Maintains | Neutral → Neutral | — | $175.65 | $177.47 | +1.0% | +1.5% | +0.5% | +0.7% | -2.0% | +3.9% |
| Feb 25 | UBS | Maintains | Neutral → Neutral | — | $166.06 | $169.91 | +2.3% | +0.9% | +4.7% | +1.7% | +0.1% | -1.6% |
| Feb 20 | TD Cowen | Maintains | Buy → Buy | — | $164.24 | $162.54 | -1.0% | +2.8% | -3.2% | +1.6% | +0.9% | +4.7% |
| Feb 20 | Mizuho | Maintains | Neutral → Neutral | — | $164.24 | $162.54 | -1.0% | +2.8% | -3.2% | +1.6% | +0.9% | +4.7% |
| Feb 19 | Barclays | Maintains | Overweight → Overweight | — | $158.00 | $154.09 | -2.5% | +3.9% | +2.8% | -3.2% | +1.6% | +0.9% |
| Feb 19 | Evercore ISI | Maintains | Outperform → Outperform | — | $158.00 | $154.09 | -2.5% | +3.9% | +2.8% | -3.2% | +1.6% | +0.9% |
| Jan 16 | Citigroup | Maintains | Buy → Buy | — | $223.47 | $223.43 | -0.0% | -1.7% | -0.7% | +3.9% | -1.2% | -2.0% |
| Jan 13 | Evercore ISI | Maintains | Outperform → Outperform | — | $218.82 | $221.66 | +1.3% | +0.1% | -1.2% | +3.3% | -1.7% | -0.7% |
| Dec 18 | Mizuho | Maintains | Neutral → Neutral | — | $195.98 | $197.32 | +0.7% | -1.1% | +1.7% | +3.0% | -0.1% | +0.1% |
| Dec 15 | Barclays | Maintains | Overweight → Overweight | — | $193.03 | $197.08 | +2.1% | +2.7% | -1.5% | +0.4% | -1.1% | +1.7% |
| Dec 15 | JP Morgan | Maintains | Neutral → Neutral | — | $193.03 | $197.08 | +2.1% | +2.7% | -1.5% | +0.4% | -1.1% | +1.7% |
| Nov 11 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $168.97 | $169.70 | +0.4% | +2.7% | -1.2% | -1.3% | -0.8% | -3.0% |
| Nov 10 | TD Cowen | Maintains | Buy → Buy | — | $168.05 | $167.14 | -0.5% | +0.5% | +2.7% | -1.2% | -1.3% | -0.8% |
| Nov 6 | Baird | Upgrade | Neutral → Outperform | — | $167.70 | $167.72 | +0.0% | +1.9% | -1.7% | +0.5% | +2.7% | -1.2% |
| Nov 6 | JP Morgan | Maintains | Neutral → Neutral | — | $167.70 | $167.72 | +0.0% | +1.9% | -1.7% | +0.5% | +2.7% | -1.2% |
| Nov 6 | Barclays | Maintains | Overweight → Overweight | — | $167.70 | $167.72 | +0.0% | +1.9% | -1.7% | +0.5% | +2.7% | -1.2% |
| Oct 17 | Mizuho | Maintains | Neutral → Neutral | — | $174.95 | $173.16 | -1.0% | +2.0% | +3.1% | +2.2% | -0.7% | +2.1% |
| Oct 6 | William Blair | Upgrade | Market Perform → Outperform | — | $177.33 | $178.15 | +0.5% | -1.3% | -2.8% | +2.0% | -0.8% | -3.0% |
| Oct 3 | Evercore ISI | Maintains | Outperform → Outperform | — | $175.36 | $176.00 | +0.4% | +1.1% | -1.3% | -2.8% | +2.0% | -0.8% |
| Oct 2 | Barclays | Upgrade | Equal Weight → Overweight | — | $170.48 | $173.25 | +1.6% | +2.9% | +1.1% | -1.3% | -2.8% | +2.0% |
| Sep 9 | Jefferies | Upgrade | Hold → Buy | — | $162.00 | $167.50 | +3.4% | -2.9% | -2.6% | +4.2% | -4.3% | -0.4% |
| Aug 8 | Evercore ISI | Maintains | Outperform → Outperform | — | $149.78 | $150.49 | +0.5% | -0.7% | +0.1% | +2.6% | +1.5% | +0.5% |
| Aug 7 | JP Morgan | Maintains | Neutral → Neutral | — | $150.33 | $153.37 | +2.0% | -0.4% | -0.7% | +0.1% | +2.6% | +1.5% |
| Aug 7 | Barclays | Maintains | Equal Weight → Equal Weight | — | $150.33 | $153.37 | +2.0% | -0.4% | -0.7% | +0.1% | +2.6% | +1.5% |
| Jul 9 | Evercore ISI | Maintains | Outperform → Outperform | — | $158.39 | $162.89 | +2.8% | +0.4% | +3.0% | -2.6% | -0.9% | -2.3% |
| Jul 9 | Citigroup | Upgrade | Neutral → Buy | — | $158.39 | $162.89 | +2.8% | +0.4% | +3.0% | -2.6% | -0.9% | -2.3% |
| May 23 | Redburn Atlantic | Upgrade | Neutral → Buy | — | $135.60 | $134.21 | -1.0% | +0.8% | +1.4% | -1.7% | +1.1% | -1.5% |
| May 8 | Barclays | Maintains | Equal Weight → Equal Weight | — | $136.97 | $140.70 | +2.7% | +3.2% | -1.8% | +3.1% | +0.7% | -3.5% |
| May 8 | Baird | Maintains | Neutral → Neutral | — | $136.97 | $140.70 | +2.7% | +3.2% | -1.8% | +3.1% | +0.7% | -3.5% |
| Apr 10 | Barclays | Maintains | Equal Weight → Equal Weight | — | $139.07 | $136.27 | -2.0% | -28.1% | -0.2% | +6.9% | -0.6% | -1.6% |
| Apr 9 | Mizuho | Maintains | Neutral → Neutral | — | $123.61 | $121.71 | -1.5% | +12.5% | -28.1% | -0.2% | +6.9% | -0.6% |
| Mar 21 | Goldman Sachs | Downgrade | Buy → Neutral | — | $165.35 | $162.94 | -1.5% | +1.2% | -0.2% | -3.4% | -1.9% | -0.1% |
| Mar 4 | Citigroup | Upgrade | Sell → Neutral | — | $163.50 | $164.07 | +0.3% | +0.5% | +2.0% | +1.0% | +3.9% | -0.5% |
| Mar 3 | Redburn Atlantic | Upgrade | Sell → Neutral | — | $165.31 | $165.89 | +0.4% | -1.1% | +0.5% | +2.0% | +1.0% | +3.9% |
| Feb 20 | Baird | Maintains | Neutral → Neutral | — | $165.00 | $165.00 | +0.0% | -1.7% | +0.5% | +4.6% | -2.0% | +0.5% |
| Feb 20 | JP Morgan | Maintains | Neutral → Neutral | — | $165.00 | $165.00 | +0.0% | -1.7% | +0.5% | +4.6% | -2.0% | +0.5% |
| Feb 20 | Barclays | Maintains | Equal Weight → Equal Weight | — | $165.00 | $165.00 | +0.0% | -1.7% | +0.5% | +4.6% | -2.0% | +0.5% |
| Feb 18 | Barclays | Maintains | Equal Weight → Equal Weight | — | $151.99 | $151.59 | -0.3% | +1.6% | +6.9% | -1.7% | +0.5% | +4.6% |
| Feb 5 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $163.12 | $165.84 | +1.7% | +1.7% | +0.2% | -1.5% | -2.4% | -3.1% |
| Feb 3 | JP Morgan | Maintains | Neutral → Neutral | — | $164.76 | $161.80 | -1.8% | -1.9% | +0.9% | +1.7% | +0.2% | -1.5% |
| Jan 23 | Goldman Sachs | Maintains | Buy → Buy | — | $168.22 | $168.90 | +0.4% | -0.8% | -1.1% | +0.5% | -1.3% | -1.2% |
| Jan 22 | William Blair | Downgrade | Outperform → Market Perform | — | $169.81 | $167.87 | -1.1% | -0.9% | -0.8% | -1.1% | +0.5% | -1.3% |
| Jan 17 | UBS | Downgrade | Buy → Neutral | — | $165.80 | $165.41 | -0.2% | -1.4% | +3.9% | -0.9% | -0.8% | -1.1% |
| Jan 14 | William Blair | Maintains | Outperform → Outperform | — | $190.14 | $179.87 | -5.4% | -6.3% | -2.3% | -4.7% | -1.4% | +3.9% |
| Dec 16 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $190.46 | $189.72 | -0.4% | -0.2% | -0.4% | -3.3% | -0.6% | +2.0% |
| Dec 13 | BofA Securities | Maintains | Neutral → Neutral | — | $194.27 | $194.17 | -0.1% | -2.0% | -0.2% | -0.4% | -3.3% | -0.6% |
| Nov 11 | TD Cowen | Maintains | Hold → Hold | — | $215.39 | $217.67 | +1.1% | +2.5% | -2.2% | -4.4% | -4.7% | -4.7% |
No insider trades available.
8-K · 7.01
! Medium
Charles River Laboratories International, Inc. -- 8-K 7.01: Regulation FD Disclosure
Charles River Laboratories plans to divest its CDMO and Cell Solutions businesses, eliminating revenue streams from advanced therapy manufacturing services and cellular materials, potentially impacting investor returns.
Feb 25
8-K
Charles River Laboratories International, Inc. -- 8-K Filing
Charles River Laboratories' Q4 2025 revenue declined 0.8% year-over-year to $994.2 million, signaling modest top-line pressure that investors should monitor alongside management's 2026 guidance.
Feb 18
8-K · 5.02
!!! Very High
Charles River Laboratories International, Inc. -- 8-K 5.02: Executive Change
Charles River Laboratories appointed Glenn Coleman as Corporate Executive Vice President and Chief Financial Officer, effective April 6, 2026, signaling leadership stability in financial operations.
Feb 18
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 3,456,244 | $596M | Added | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 3,202,204 | $552M | New | Mar 2026 |
| 3 | Invesco Ltd. | 2,397,252 | $414M | Reduced | Mar 2026 |
| 4 | Vanguard Portfolio Management Llc | 2,294,670 | $396M | New | Mar 2026 |
| 5 | Allspring Global Investments Holdings, Llc | 1,993,316 | $349M | — | Mar 2026 |
| 6 | Morgan Stanley | 1,585,640 | $316M | Reduced | Dec 2025 |
| 7 | Ariel Investments, Llc | 1,444,183 | $249M | Added | Mar 2026 |
| 8 | Citadel Advisors Llc | 1,212,152 | $209M | Added | Mar 2026 |
| 9 | Bank Of America Corp /de/ | 1,135,027 | $196M | Reduced | Mar 2026 |
| 10 | Millennium Management | 934,045 | $161M | Added | Mar 2026 |
| 11 | Neuberger Berman Group Llc | 874,378 | $151M | Added | Mar 2026 |
| 12 | Cooke & Bieler Lp | 867,920 | $150M | Added | Mar 2026 |
| 13 | Amundi | 773,315 | $133M | New | Mar 2026 |
| 14 | Sei Investments Co | 757,129 | $131M | — | Mar 2026 |
| 15 | Victory Capital Management Inc | 743,346 | $128M | Added | Mar 2026 |
| 16 | Arrowstreet Capital, Limited Partnership | 737,030 | $127M | Reduced | Mar 2026 |
| 17 | Ubs Group Ag | 731,465 | $126M | Added | Mar 2026 |
| 18 | Clearbridge Investments, Llc | 632,624 | $109M | Added | Mar 2026 |
| 19 | Alyeska Investment Group, L.p. | 558,633 | $96M | Reduced | Mar 2026 |
| 20 | Van Berkom & Associates Inc. | 501,152 | $86M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Invesco Small Cap Value Fund | 902,198 | $190M | Jan 2026 |
| 2 | Invesco S&P 500 Equal Weight ETF | 818,689 | $172M | Jan 2026 |
| 3 | Invesco Value Opportunities Fund | 695,387 | $146M | Jan 2026 |
| 4 | VANGUARD WINDSOR FUND | 683,031 | $144M | Jan 2026 |
| 5 | Fidelity 500 Index Fund | 626,319 | $112M | Feb 2026 |
| 6 | iShares Core S&P 500 ETF | 633,346 | $109M | Mar 2026 |
| 7 | Ariel Fund | 523,713 | $90M | Mar 2026 |
| 8 | Columbia Disciplined Core Fund | 320,720 | $68M | Jan 2026 |
| 9 | iShares Biotechnology ETF | 362,165 | $62M | Mar 2026 |
| 10 | VANGUARD SELECTED VALUE FUND | 291,200 | $61M | Jan 2026 |
| 11 | ClearBridge Select Fund | 243,548 | $51M | Jan 2026 |
| 12 | Columbia Small Cap Growth Fund | 248,280 | $44M | Feb 2026 |
| 13 | U.S. Targeted Value Portfolio | 210,103 | $44M | Jan 2026 |
| 14 | Dimensional U.S. Targeted Value ETF | 187,627 | $39M | Jan 2026 |
| 15 | U.S. SMALL CAP PORTFOLIO | 176,629 | $37M | Jan 2026 |
| 16 | iShares Russell Mid-Cap ETF | 187,202 | $32M | Mar 2026 |
| 17 | Ariel Appreciation Fund | 171,201 | $30M | Mar 2026 |
| 18 | U.S. SMALL CAP VALUE PORTFOLIO | 135,936 | $29M | Jan 2026 |
| 19 | Dimensional U.S. Small Cap ETF | 134,096 | $28M | Jan 2026 |
| 20 | MFS New Discovery Fund | 151,776 | $27M | Feb 2026 |
Valuation
Market Cap
$8.91B
Enterprise Value
$11.37B
P/E (TTM)
-62.66x
Forward P/E
16.70x
PEG Ratio
0.04x
P/B
2.86x
P/S
2.28x
P/FCF
17.68x
EV/EBITDA
12.48x
Shares Out
49.6M
Financials (TTM)
Revenue
$4.02B
Net Income
-$144.3M
EBITDA
$911.2M
Free Cash Flow
$518.5M
Op Cash Flow
$737.6M
EPS Basic
$-2.91
EPS Diluted
$-2.91
EPS Forward
$11.08
Gross Margin
30.5%
Op Margin
12.7%
Net Margin
-3.6%
Balance Sheet
Total Assets
$7.14B
Total Liab.
$3.92B
Total Equity
$3.21B
Cash
$213.8M
LT Debt
$2.55B
Book Value/Sh
$64.79
Debt/Equity
0.97x
Current Ratio
1.29
Quick Ratio
1.02
Returns & Growth
ROE
-4.6%
ROA
-2.0%
ROIC
8.4%
Rev Growth YoY
-0.9%
EPS Growth YoY
-1555.0%
Price Returns
2W
+13.6%
1M
+8.2%
3M
+1.2%
6M
+1.4%
12M
+33.2%
Technicals
52W High
$228.88
52W Low
$144.26
50d MA
$174.36
200d MA
$177.89
RSI (14)
54.40
ATR (14)
$7.24
Beta
1.62
Avg Volume
895K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$205.43
High
$260.00
Low
$175.00
Median
$200.00
Data updated apr 25, 2026 3:15am
· Source: financialmodelingprep.com